CTLA4 and posterior cortical atrophy: We then analyzed the efficacy of immunosuppressant treatment for these two immune checkpoints according to the immunophenotype scores of PCa patients obtained from the TCIA database and found that the HDR group would be better treated with either a PD1 inhibitor or a CTLA4 inhibitor or a combination of both (Fig. 8e–h).